The impact of interferon-free direct-acting antivirals on clinical outcome after curative treatment for hepatitis C virus-associated hepatocellular carcinoma: Comparison with interferon-based therapy

Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection

(2017) Hidenori Toyoda et al.   HEPATOLOGY

Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis

(2017) Kazuaki Chayama et al.   JOURNAL OF GASTROENTEROLOGY

The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy

(2017) Yuko Nagaoki et al.   PLoS One

Daclatasvir/asunaprevir/beclabuvir fixed-dose combination in Japanese patients with HCV genotype 1 infection

(2016) Joji Toyota et al.   JOURNAL OF GASTROENTEROLOGY

The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II/III study

(2016) Hiromitsu Kumada et al.   JOURNAL OF GASTROENTEROLOGY

Development of hepatocellular carcinoma in patients with hepatitis C virus infection who achieved sustained virological response following interferon therapy: A large-scale, long-term cohort study

(2016) Yuko Nagaoki et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals

(2016) Fabio Conti et al.   JOURNAL OF HEPATOLOGY

The impact of direct-acting antivirals on early tumor recurrence after radiofrequency ablation in hepatitis C-related hepatocellular carcinoma

(2016) Tatsuya Minami et al.   JOURNAL OF HEPATOLOGY

Hepatocellular carcinoma recurrence after treatment with direct-acting antivirals: First, do no harm by withdrawing treatment

(2016) Harrys A. Torres et al.   JOURNAL OF HEPATOLOGY

High incidence of hepatocellular carcinoma following successful interferon-free antiviral therapy for hepatitis C associated cirrhosis

(2016) Helder Cardoso et al.   JOURNAL OF HEPATOLOGY

Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy

(2016) María Reig et al.   JOURNAL OF HEPATOLOGY

Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection

(2016) Masahiro Kobayashi et al.   JOURNAL OF MEDICAL VIROLOGY

Randomized trial of interferon- and ribavirin-free ombitasvir/paritaprevir/ritonavir in treatment-experienced hepatitis C virus-infected patients

(2015) Kazuaki Chayama et al.   HEPATOLOGY

Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis

(2015) Hiromitsu Kumada et al.   HEPATOLOGY

Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial

(2015) Masashi Mizokami et al.   LANCET INFECTIOUS DISEASES

Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection

(2014) Hiromitsu Kumada et al.   HEPATOLOGY

Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial

(2014) Masao Omata et al.   JOURNAL OF VIRAL HEPATITIS

Radiofrequency Ablation for Hepatocellular Carcinoma: 10-Year Outcome and Prognostic Factors

(2011) Shuichiro Shiina et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Meta-analysis: interferon improves outcomes following ablation or resection of hepatocellular carcinoma

(2010) A. K. Singal et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Effect of pegylated interferon therapy on intrahepatic recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma

(2010) Hiroaki Hagihara et al.   International Journal of Clinical Oncology

Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): A meta-regression approach

(2010) Ying-Chun Shen et al.   JOURNAL OF HEPATOLOGY

Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b

(2010) Tomokazu Kawaoka et al.   JOURNAL OF HEPATOLOGY

Effects of interferon alpha treatment on recurrence and survival after complete resection or ablation of hepatocellular carcinoma: A meta-analysis of randomized controlled trials

(2009) Chuan-Hai Zhang et al.   INTERNATIONAL JOURNAL OF CANCER